{
    "symbol": "CGEN",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-27 13:10:21",
    "content": " In terms of what success looks like, we believe that even if we repeat the 12% of our response rate in patients with liver metastases, and also take into consideration other clinically relevant endpoints, such as progression free survival, durability of antitumor activity, death of response, safety, presence of coexisting adverse prognostic features such as KRAS mutation, we would be informed our next step for a potential path to registration ideally with the right partner."
}